RESEARCH-USE BIOSIMILAR ANTIBODY
Tixagevimab
Monoclonal antibody · IgG1
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
TARGETSARS-CoV-2 Spike RBD
YMonoclonal antibody
CATALOGSC-BS-090
CATALOG NUMBERSC-BS-090
MOLECULAR WEIGHTApprox. 146.48 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
Tixagevimab is a recombinant research-use antibody directed against SARS-CoV-2 Spike RBD.